April 26th 2024
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Frontline Acalabrutinib Improves Quality-Adjusted Survival in CLL
November 3rd 2021Patients treated with acalabrutinib monotherapy had a significantly longer mean duration of time spent without toxicity compared with those treated with chlorambucil plus obinutuzumab in the phase 3 ELEVATE-TN trial.
Read More
IGHV and TP53 Remain Important Prognostic CLL Biomarkers
September 9th 2021IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.
Read More
Zanubrutinib Demonstrates Activity in Patients With CLL/SLL and Del(17p)
September 8th 2021Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, was safe and effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma carrying chromosome 17p13.1 deletion.
Read More
SEQUOIA Study Update: Zanubrutinib Prolongs PFS in Chronic Lymphocytic Leukemia
July 30th 2021Treatment with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia led to a significant improvement in progression-free survival, meeting the primary end point of the phase 3 SEQUOIA clinical trial.
Read More